Boston Scientific International Sa

NATICK, Massachusetts, June 10, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced the market launch and first implants of its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries.